MELBOURNE, AUSTRALIA / ACCESSWIRE / /Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company ...
Some results have been hidden because they may be inaccessible to you